David T. MacLaughlin

10.1k total citations · 2 hit papers
120 papers, 7.8k citations indexed

About

David T. MacLaughlin is a scholar working on Reproductive Medicine, Public Health, Environmental and Occupational Health and Molecular Biology. According to data from OpenAlex, David T. MacLaughlin has authored 120 papers receiving a total of 7.8k indexed citations (citations by other indexed papers that have themselves been cited), including 59 papers in Reproductive Medicine, 57 papers in Public Health, Environmental and Occupational Health and 46 papers in Molecular Biology. Recurrent topics in David T. MacLaughlin's work include Reproductive Biology and Fertility (53 papers), Ovarian function and disorders (35 papers) and Genetic and Clinical Aspects of Sex Determination and Chromosomal Abnormalities (23 papers). David T. MacLaughlin is often cited by papers focused on Reproductive Biology and Fertility (53 papers), Ovarian function and disorders (35 papers) and Genetic and Clinical Aspects of Sex Determination and Chromosomal Abnormalities (23 papers). David T. MacLaughlin collaborates with scholars based in United States, South Korea and United Kingdom. David T. MacLaughlin's co-authors include Patricia K. Donahoe, David B. Seifer, Mary Lee, Frederic I. Preffer, Benjamin P. Christian, George S. Richardson, David Dombkowski, Rafael Pieretti‐Vanmarcke, Richard C. Ragin and Robert L. Martuza and has published in prestigious journals such as New England Journal of Medicine, Cell and Proceedings of the National Academy of Sciences.

In The Last Decade

David T. MacLaughlin

119 papers receiving 7.5k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Isolation of the bovine and human genes for müllerian inhibiting substance and expression of the human gene in animal cells

1986 836 citations T F Manganaro, David T. MacLaughlin et al. profile →
Ovarian cancer side population defines cells with stem cell-like characteristics and Mullerian Inhibiting Substance responsiveness

2006 612 citations Paul P. Szotek, Rafael Pieretti‐Vanmarcke et al. Proceedings of the National Academy of Sciences profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
David T. MacLaughlin United States	47	3.8k	3.2k	3.1k	1.9k	874	120	7.8k
Kyle E. Orwig United States	48	4.8k 1.3×	3.6k 1.1×	4.3k 1.4×	2.5k 1.3×	144 0.2×	147	7.7k
Yoshitake Nishimune Japan	48	3.5k 0.9×	6.1k 1.9×	2.9k 0.9×	3.2k 1.7×	658 0.8×	215	11.0k
Anthony J. Mason United States	35	1.5k 0.4×	4.8k 1.5×	1.0k 0.3×	1.2k 0.6×	664 0.8×	53	7.6k
Dagmar Wilhelm Australia	46	1.8k 0.5×	5.4k 1.7×	1.1k 0.4×	3.7k 2.0×	705 0.8×	92	7.6k
Yasuhisa Matsui Japan	42	1.1k 0.3×	6.9k 2.2×	1.4k 0.5×	2.6k 1.4×	801 0.9×	149	9.3k
Susanna Dolci Italy	37	1.7k 0.4×	2.8k 0.9×	1.5k 0.5×	1.8k 0.9×	291 0.3×	109	4.9k
Kirsi Sainio Finland	31	854 0.2×	3.2k 1.0×	933 0.3×	1.0k 0.5×	991 1.1×	59	5.2k
Harshida Bhatt United States	8	957 0.2×	2.2k 0.7×	639 0.2×	711 0.4×	435 0.5×	9	4.2k
Antonino Forabosco Italy	34	908 0.2×	2.5k 0.8×	1.3k 0.4×	2.1k 1.1×	163 0.2×	119	4.5k
Kimiko Inoue Japan	59	4.1k 1.1×	8.2k 2.6×	5.6k 1.8×	3.8k 2.0×	152 0.2×	156	11.9k

Countries citing papers authored by David T. MacLaughlin

Since Specialization

Citations

This map shows the geographic impact of David T. MacLaughlin's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by David T. MacLaughlin with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites David T. MacLaughlin more than expected).

Fields of papers citing papers by David T. MacLaughlin

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by David T. MacLaughlin. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by David T. MacLaughlin. The network helps show where David T. MacLaughlin may publish in the future.

Co-authorship network of co-authors of David T. MacLaughlin

This figure shows the co-authorship network connecting the top 25 collaborators of David T. MacLaughlin. A scholar is included among the top collaborators of David T. MacLaughlin based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with David T. MacLaughlin. David T. MacLaughlin is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Song, Jae Yen, Sang-Il Kim, David Pépin, et al.. (2017). Müllerian inhibiting substance inhibits an ovarian cancer cell line via β-catenin interacting protein deregulation of the Wnt signal pathway. International Journal of Oncology. 50(3). 1022–1028. 12 indexed citations

Anttonen, Mikko, Anniina Färkkilä, David T. MacLaughlin, et al.. (2011). Anti-Müllerian hormone inhibits growth of AMH type II receptor-positive human ovarian granulosa cell tumor cells by activating apoptosis. Laboratory Investigation. 91(11). 1605–1614. 45 indexed citations

Fujino, Akihiro, et al.. (2008). Cell migration and activated PI3K/AKT-directed elongation in the developing rat Müllerian duct. Developmental Biology. 325(2). 351–362. 33 indexed citations

Kow, Lee‐Ming, Cristina Florea, Marlene Schwanzel‐Fukuda, et al.. (2007). Development of a Sexually Differentiated Behavior and Its Underlying CNS Arousal Functions. Current topics in developmental biology. 79. 37–59. 9 indexed citations

Kantarci, Sibel, Lihadh Al‐Gazali, R. Sean Hill, et al.. (2007). Mutations in LRP2, which encodes the multiligand receptor megalin, cause Donnai-Barrow and facio-oculo-acoustico-renal syndromes. Nature Genetics. 39(8). 957–959. 238 indexed citations

Szotek, Paul P., Rafael Pieretti‐Vanmarcke, Peter T. Masiakos, et al.. (2006). Ovarian cancer side population defines cells with stem cell-like characteristics and Mullerian Inhibiting Substance responsiveness. Proceedings of the National Academy of Sciences. 103(30). 11154–11159. 612 indexed citations breakdown →

Hoshiya, Makiko, Benjamin P. Christian, William J. Cromie, et al.. (2003). Persistent Mullerian duct syndrome caused by both a 27‐bp deletion and a novel splice mutation in the MIS type II receptor gene. Birth Defects Research Part A Clinical and Molecular Teratology. 67(10). 868–874. 28 indexed citations

Donahoe, Patricia K., Trent R. Clarke, Jose M. Teixeira, Shyamala Maheswaran, & David T. MacLaughlin. (2003). Enhanced purification and production of Müllerian inhibiting substance for therapeutic applications. Molecular and Cellular Endocrinology. 211(1-2). 37–42. 28 indexed citations

Sriraman, Venkataraman, En-Mei Niu, Jonathan R. Matias, et al.. (2001). Müllerian Inhibiting Substance Inhibits Testosterone Synthesis in Adult Rats. Journal of Andrology. 22(5). 750–758. 65 indexed citations

10.

Segev, Dorry L., Yasunori Hoshiya, Antonia E. Stephen, et al.. (2001). Müllerian Inhibiting Substance Regulates NFκB Signaling and Growth of Mammary Epithelial Cells in Vivo. Journal of Biological Chemistry. 276(29). 26799–26806. 53 indexed citations

11.

Segev, Dorry L., Trinh T. Tran, Mary Kenneally, et al.. (2000). Müllerian Inhibiting Substance Inhibits Breast Cancer Cell Growth through an NFκB-mediated Pathway. Journal of Biological Chemistry. 275(37). 28371–28379. 116 indexed citations

12.

Lee, Mary, Patricia K. Donahoe, Tomonobu Hasegawa, et al.. (1996). Mullerian inhibiting substance in humans: normal levels from infancy to adulthood.. The Journal of Clinical Endocrinology & Metabolism. 81(2). 571–576. 336 indexed citations

13.

Puls, Larry E., et al.. (1994). Recurrent Ovarian Sex Cord Tumor with Annular Tubules: Tumor Marker and Chemotherapy Experience. Gynecologic Oncology. 54(3). 396–401. 24 indexed citations

14.

Catlin, Elizabeth A., et al.. (1993). Identification of a receptor for human müllerian inhibiting substance.. Endocrinology. 133(6). 3007–3013. 10 indexed citations

15.

Catlin, Elizabeth A., David T. MacLaughlin, & Patricia K. Donahoe. (1993). Müllerian inhibiting substance: New perspectives and future directions. Microscopy Research and Technique. 25(2). 121–133. 11 indexed citations

16.

Gustafson, Michael L., Mary M. Lee, Robert E. Scully, et al.. (1992). Müllerian Inhibiting Substance as a Marker for Ovarian Sex-Cord Tumor. New England Journal of Medicine. 326(7). 466–471. 109 indexed citations

17.

Meyers-Wallen, Vicki N., T F Manganaro, Takeshi Kuroda, et al.. (1991). The Critical Period for Mullerian Duct Regression in the Dog Embryo1. Biology of Reproduction. 45(4). 626–633. 26 indexed citations

18.

Prince, Richard L., David T. MacLaughlin, Randall D. Gaz, & R. Neer. (1991). Lack of Evidence for Estrogen Receptors in Human and Bovine Parathyroid Tissue. The Journal of Clinical Endocrinology & Metabolism. 72(6). 1226–1228. 19 indexed citations

19.

Rein, Mitchell S., et al.. (1990). Fibroid and myometrial steroid receptors in women treated with gonadotropin-releasing hormone agonist leuprolide acetate. Fertility and Sterility. 53(6). 1018–1023. 80 indexed citations

20.

MacLaughlin, David T., et al.. (1987). Analysis of Proteins Secreted by the Human Endometrium In Vivo and In Vitro. Advances in experimental medicine and biology. 230. 151–165. 1 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact